OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
+3.90%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
Market Cap
$164.16M
MomentumView details →
1D Return
+3.90%
YTD Return
−57.27%
RSI (14)
38.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
Market Cap
$164.16M
RSI (14)
38.7
MomentumView details →
1D Return
+3.90%
YTD Return
−57.27%
SummaryUpdated Jun 1, 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a late-stage biopharmaceutical company founded in 2010 and headquartered in Iselin, New Jersey. Originally incorporated as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics in November 2018 to reflect its strategic pivot toward ophthalmology. The company went public in 2016 and has evolved from a broader oncology focus to specialize exclusively in developing monoclonal antibody treatments for eye diseases, particularly retinal disorders that can cause blindness.
Similar companies
Latest newsMore news →
Lawrence A. Kenyon departed as Chief Financial Officer, Treasurer and Corporate Secretary of Outlook Therapeutics, Inc. effective September 1, 2026, and Kevin Lundquist was appointed as his successor, effective the same date.9d agoOutlook Therapeutics reported Q3 FY2026 net revenue of $9 thousand, down from $1.505 million in Q3 FY2025, with a GAAP net loss of $20.3 million ($0.15 per diluted share) and a non-GAAP adjusted net loss of $10.9 million ($0.09 per diluted share).22d ago